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Introduction
There are numerous randomized, controlled trials and several
meta-analyses evaluating drug therapy for stress ulcer pro-
phylaxis [1]. While these publications have shown significant
benefit with using prophylaxis, a number of issues still remain
unresolved. For example, Cook et al. performed a meta-analy-
sis of published and unpublished research, and they con-
cluded that sucralfate might be as effective as pH-altering
medication in preventing stress-induced bleeding, with a
lower incidence of pneumonia and mortality [1]. In a subse-
quent multicenter, randomized trial involving 1200 patients,
Cook  et al. found a lower incidence of clinically important
gastrointestinal bleeding with ranitidine compared with
sucralfate (relative risk, 0.44; 95% confidence interval,
0.21–0.92; P = 0.02), with no differences in pneumonia or
mortality [2].
In contrast to the multiple, and often conflicting, studies of
stress ulcer prophylaxis conducted in general medical and
surgical populations, decisions concerning appropriate stress
H2 = histamine-2; ICU = intensive care unit.
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ulcer prophylaxis in trauma patients are further complicated
by a lack of randomized, controlled trials using clinically
important bleeding (e.g. requiring transfusion, hemodynamic
instability) as an endpoint. Furthermore, while many studies
involving more heterogeneous patient populations included
trauma patients, there were often insufficient numbers of
these patients to draw any definitive conclusions. The relative
lack of prospective studies involving trauma patients is some-
what surprising given the relationship between injury and gas-
trointestinal ulceration that was well described during the
Korean and Vietnam wars [3,4].
Retrospective analyses of large numbers of trauma patients
have found the incidence of stress-induced bleeding to range
from 0.05 to 2.3% [5,6]. The lower figure was based on
patients with clinically evident complications of bleeding such
as perforation or blood loss requiring transfusion [5]. The
higher figure was taken from an abstract in which gastro-
intestinal bleeding was not defined, so there is no way of
knowing whether it led to any clinically important problems
[6]. Both of these figures could, however, be misleading due
to the difficulties in extracting such information from retro-
spective chart reviews or trauma registries.
A number of risk factors have been associated with stress
ulceration in trauma patients, including sex, lung injury or
pneumonia, renal or hepatic failure, sepsis, and severity of
injury [5,6]. Two factors that appear to be independently pre-
dictive of bleeding are severe injury as defined by an Injury
Severity Score greater than 16 and single-system injuries
(e.g. head and spinal cord injuries) of the central nervous
system [5]. However, the use of routine stress ulcer prophy-
laxis in these groups has both proponents [7] and opponents
[8]. The diversity of opinion is partially explained by method-
ological problems of the available studies. For example, the
incidence of clinically important bleeding is difficult to esti-
mate since many of these studies did not distinguish between
various types of occult (microscopic), overt (macroscopic),
and clinically important bleeding [9–14].
Once the decision is made to use stress ulcer prophylaxis, the
clinician must decide between histamine-2 (H2)-antagonists,
antacids, sucralfate, and proton pump inhibitors. There have
been no prospective studies of adequate power involving
trauma patients to determine whether there are important dif-
ferences between these agents in preventing stress-induced
bleeding complications. Some studies have attempted to
determine whether there might be important differences in the
adverse effect profiles of the medications, particularly nosoco-
mial pneumonia. In general, there have been no significant dif-
ferences in pneumonia between the various agents [15–17],
although the appropriate diagnostic criteria for pneumonia in
clinical investigations have been an issue of debate.
Given the lack of consensus on virtually every aspect of
stress ulcer prophylaxis, a survey was developed to assess
current prescribing practices in Level I trauma centers in the
United States. Additionally, the survey had questions con-
cerning intra-institutional evaluations of prescribing practices.
Materials and methods
A survey was developed that contained questions related to
institutional prescribing and evaluation of stress ulcer prophy-
laxis. The survey was intended to delineate these practices at
the 188 Level I trauma centers (at the time of the present
survey) in the United States. The survey was limited to the
front and back of one sheet of paper to encourage comple-
tion. There were 11 questions concerning stress ulcer prophy-
laxis, although several of the questions contained subparts.
For example, one question evaluating institutional approaches
asked ‘Does your institution have written guidelines for stress
ulcer prophylaxis?’. If the answer was yes, then the respon-
dent was questioned on various aspects of these guidelines
(i.e. have the guidelines been updated/reviewed in the past
2 years?, do they include recommendations for intensive care
unit [ICU] and non-ICU settings?, etc.) A majority of the ques-
tions were in yes/no format; however, some questions
requested information stated as a percentage value. For
example, ‘What percentage of patients discharged from the
ICU to non-ICU settings remain on stress ulcer prophylaxis?’.
The responses included 0–25%, 26–50%, 51–75% and
76–100%. The survey was approved by the human subjects
committee (exempted from committee review).
The instrument was reviewed by several experienced trauma
surgeons and pharmacists (who were not involved with this
project) prior to mass distribution to assure validity and reliabil-
ity. Changes to the instrument were then made accordingly.
The survey was mailed to the trauma coordinator at each Level
I trauma center. A self-addressed, stamped envelope was
included to encourage return of the completed survey.
Results
A total of 188 surveys were distributed to Level I trauma
centers; 119 were returned, producing a response rate of
63%. Fifty-seven percent of the hospitals surveyed had more
than 400 beds, and 29% of hospitals had between 200 and
399 beds. A further description of the hospitals surveyed,
particularly a differentiation between the number of ICU beds
versus trauma beds, is presented in Table 1.
Eighty-six percent of Level I trauma centers stated that med-
ications for stress ulcer prophylaxis are used in a vast majority
of trauma patients admitted to the ICU. The prescribing prac-
tices for stress ulcer prophylaxis are further described in
Table 2. The most common type of injury where stress ulcer
prophylaxis was routinely administered was a head injury,
which is further described in Table 3.
Forty-five percent of the centers have recommendations for
both ICU and non-ICU settings. Thirty-seven percent of insti-
tutions have written guidelines for stress ulcer prophylaxis,528
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with approximately one-half of those stating that their guide-
lines have been reviewed or updated within the past 2 years.
Forty-five percent of responders are either considering or
developing guidelines for their respective institutions.
Sixty-five percent of institutions stated that there is one pre-
ferred medication for stress ulcer prophylaxis. For those insti-
tutions, H2 antagonists were the most popular at 71%.
Sucralfate was the agent of choice for 25% of institutions,
while omeprazole and antacids were preferred for 3 and 1%,
respectively. A breakdown of the route of administration for
each agent is presented in Table 4.
Twenty-seven percent of institutions evaluated the incidence
of clinically important bleeding, defined as the need for trans-
fusion or hemodynamic changes associated with bleeding.
Fifteen percent of those institutions limited their evaluation to
patients receiving stress ulcer prophylaxis, and 69% included
both ICU and non-ICU patients. Twenty-nine percent of insti-
tutions routinely used gastric pH measurements (i.e. pH
Table 2
Stress ulcer prophylaxis in intensive care unit (ICU) and non-ICU settings
Institutions (%) stating percentage of patients
0–25% 26–50% 51–75% 76–100%
ICU trauma patients received stress ulcer prophylaxis 8 4 11 77
Non-ICU trauma patients received stress ulcer prophylaxis 39 21 28 12
Patients discharged from the ICU to non-ICU settings remained  33 28 25 14
on stress ulcer prophylaxis
Table 3
Injuries where stress ulcer prophylaxis is routinely administered*
Do not have substantial 
Injury Yes No numbers of this injury
Head injury 106 (90%) 5 (4%) 7 (6%)
Spinal cord injury 100 (85%) 6 (5%) 11 (10%)
Thermal injury 62 (57%) 6 (6%) 40 (37%)
Multiple trauma 102 (88%) 10 (9%) 4 (3%)
Hepatic injury with need for partial resection 77 (69%) 12 (11%) 23 (20%)
* Data are expressed as the number of institutions responding to the question (percentage of responders).
Table 4
Description of the route of administration for each institution’s
preferred agent*
Histamine-2 antagonist
Intermittent intravenous 40
Intravenous infusion 27
Oral 15
Feeding tube 16
Sucralfate
Oral 18
Nasogastric tube 24
Omeprazole
Oral 2
Nasogastric tube 2
Enteral tube 3
Other (antacid) 1
* Responders were permitted to check more than one administration
route for their institution’s preferred agent.
Table 1
Description of the institutions surveyed*
Institutions (%) stating number of beds
<20 20–29  30–39  >40 
beds beds beds beds
Number of ICU beds 17 16 16 52
Number of trauma beds 47 24 7 23
* The number of intensive care unit (ICU) beds refers to the total ICU
beds for the hospital; the number of trauma beds was intended to
delineate ICU trauma beds.529
paper, pH sensor, gastric tonometry) for monitoring pH-
altering agents when such measurements were feasible.
Discussion
One hundred and nineteen surveys were returned from Level I
trauma centers, yielding a total response rate of 63%. The
results obtained from the present survey indicated that pro-
phylaxis is used in a high percentage of patients at Level I
trauma centers, particularly in the ICU. Part of the explanation
for this widespread prescribing may be due to the lack of well-
defined risk factors for stress-induced bleeding in trauma
patients. Another explanation for the widespread prescribing
of medications for stress ulcer prophylaxis in trauma patients
may be the lack of intra-institutional data concerning the inci-
dence of clinically important bleeding. Only 27% of the institu-
tions surveyed evaluated the incidence of clinically important
bleeding. Of those institutions, the majority (85%) evaluated
all ICU patients for potential bleeding, irrespective of whether
the patients were receiving stress ulcer prophylaxis.
While a number of institutions had a preferred medication for
prophylaxis, there were usually no restrictions placed on the
choice of medication. It is difficult to state that there is a clear
agent of choice for stress ulcer prophylaxis in any population
based on available research in general medical/surgical
patients, and even less reason to recommend a particular
agent in trauma patients. The largest randomized, controlled
trial to date was conducted by Cook et al. [2] This study,
which involved a heterogeneous group of patients at risk for
stress ulcer prophylaxis, found ranitidine to be more effective
than sucralfate. However, an earlier meta-analysis by some of
those authors suggested no substantial differences in effi-
cacy between the available agents [1].
The present survey revealed that H2-antagonists were the
preferred agent in Level I trauma centers, followed by sucral-
fate and, finally, omeprazole. A limited number of institutions
have reviewed their guidelines within the past 2 years, there-
fore it is unclear whether H2-antagonists have always been
the preferred agents or whether guidelines have been
changed due to the recent findings of Cook et al. [2]. Given
the lack of consensus as to the most appropriate agent for
prophylaxis, it seems reasonable to make the decision at the
local level based on cost, convenience, and adverse effects.
The number of patients receiving stress ulcer prophylaxis in
non-ICU settings is a cause for concern. Forty percent of
institutions stated that non-ICU trauma patients receive stress
ulcer prophylaxis more than 50% of the time. In the over-
whelming majority of published studies concerning stress
ulcer prophylaxis, the prophylactic medication was discontin-
ued when a patient was transferred out of the ICU. The
present report showed that 39% of institutions have greater
than one-half of their patients discharged from ICU to non-
ICU settings remaining on stress ulcer prophylaxis. While
there have been few controlled studies of stress ulcer pro-
phylaxis in non-ICU settings, indirect evidence (i.e. routine
discontinuation of prophylaxis in published investigations)
suggests that most experts believe the risk of clinically impor-
tant bleeding is too low to justify continued prophylaxis.
The medications used for stress ulcer prophylaxis have associ-
ated costs and adverse effects that must be considered when
contemplating the continuation of prophylaxis. The drug-related
costs are not always obvious. For example, since sucralfate
acts locally it would be expected to have few systemic adverse
effects, but it may result in clogged feeding tubes that need to
be replaced. In this example, there is the cost of the medica-
tion, the cost of the feeding tube, and the cost of the personnel
time required to replace the tube. Second, the most popular
medication class and route of administration for stress ulcer
prophylaxis, according to our survey, are H2-antagonists by
intravenous injection. The additional costs of intravenous
tubing, infusion pumps, and personnel time must be consid-
ered when addressing the total cost of therapy.
Of those institutions that have substantial numbers of single-
system type injuries such as burns, central nervous system
damage, or hepatic damage, stress ulcer prophylaxis is rou-
tinely implemented. It is difficult to argue, at least in the ICU
setting, against such use given the paucity of randomized
investigations conducted in these populations using an end-
point of clinically important bleeding. However, it is reason-
able to set local guidelines based on some type of severity of
injury scale, since the risk of bleeding appears to be corre-
lated with severity of injury [5]. In one of the largest prospec-
tive trials to date, respiratory failure (i.e. mechanical ventilation
for >48 hours) and coagulopathy (i.e. platelet count
<50,000 mm3, or an International Normalized Ratio >1.5 or a
partial thromoboplastin time >2 times the control value) were
found to be independent predictors of clinically important
bleeding in a heterogeneous population of medical/surgical
patients [18]. Although this requires further study, it is possi-
ble that respiratory failure and coagulopathy may serve as
adequate predictors of bleeding in trauma patients as well as
in these mixed populations.
The lack of consensus with regards to appropriate stress
ulcer prophylaxis is apparent in this survey of Level I trauma
centers. Given the limitations of the survey instrument, it
cannot be stated with certainty that the 63% of centers
responding to the survey represent Level I trauma centers
as a whole with regards to size, to geographic location,
and to survey responses. It does seem unlikely, however,
that the basic results would change substantially with such
additional information given that the one area of consis-
tency in responses was the high percentage of trauma
patients in the ICU who were thought to be in need of pro-
phylaxis. Most other aspects of prophylaxis, including the
choice of medication, the route of administration, and the
discontinuation of prophylaxis upon ICU discharge, varied
among institutions.
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The varying prescribing patterns noted with this survey of
trauma centers are consistent with the results obtained from
another survey involving a more heterogeneous group of critical
care physicians. Lam et al. surveyed members of the Society of
Critical Care Medicine who listed anesthesiology, internal med-
icine, or surgery as their primary specialty [19]. The survey was
sent to 1268 physicians, and had a response rate of 26%. The
diversity of the practice areas of the physicians under study
was evident in the respondents’ reasons for initiating stress
ulcer prophylaxis. Using a checklist of 12 possible reasons for
prophylaxis (plus an ‘other’ category), at least 20% of respon-
dents chose each listed risk factor as sufficient justification for
prophylaxis. Several reasons were given for the choice of
agent, including ease of administration, clinical effectiveness,
cost-effectiveness, and formulary considerations. Despite the
different response rates and physician groups surveyed, the
major results and conclusions of Lam et al. [19] were similar to
those reported in this evaluation (i.e. a lack of consensus
regarding stress ulcer prophylaxis prescribing).
The number of institutions performing evaluations of stress
ulcer prophylaxis was less than 50% of those surveyed. Med-
ications, however, do not guarantee prevention of stress-
induced bleeding. Additionally, the medications have
potential adverse effects and associated costs of administra-
tion. Therefore, periodic examination of prescribing and
bleeding patterns is indicated. For those institutions develop-
ing or revising stress ulcer prophylaxis guidelines, compre-
hensive recommendations have been developed that may
facilitate this process [20].
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Key messages
• There is a lack of consensus regarding stress ulcer
prophylaxis in trauma patients
• Many patients in non-ICU settings still receive stress
ulcer prophylaxis
• H2-blockers are the preferred agent for many institu-
tions